Cholesterol and triglyceride-lowering drug candidates discovered by Shanghai Institute of Materia Medica

Cardiovascular disease is harmful to health, and dyslipidemia caused by high cholesterol is one of the major risks of death from cardiovascular disease

On April 14, Liu Hong's research group from Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and the Yellow River research group, published a paper entitled Identification and evaluation of a lipid-lowering small compound in preclinical models and in a Phase I trial on Cell Metabolism.

In the early stage, Liu Hong's research group, Wang Yiping's research group and Jiang Hualiang's research group cooperated to develop a lipid-lowering candidate drug DC371739 (a new drug) with China's independent intellectual property rights through multiple rounds of structural transformation and drugability optimization

Liu Hong's research group and Yellow River research group have carried out research on the lipid-lowering mechanism of the candidate drug DC371739

Statins can increase the expression of PCSK9 protein and affect their lipid-lowering activity during clinical use

The research work is supported by the National Natural Science Foundation of China, the Key Project of Lingang Laboratory, and the Shanghai Science and Technology Commission

Schematic diagram of the mechanism of action of DC371739